Press Releases
Publications
News Articles
Media Kit
Scipher Medicine® Showcases New Data at EULAR 2024
WALTHAM, Mass., June 13, 2024 Scipher Medicine, a company focused on proprietary AI and network biology platform solutions to transform patient care, is attending and presenting at the annual European Alliance of Associations for Rheumatology (EULAR) conference in...
Dr. Reginald Seeto Appointed as CEO and President, to Lead Scipher Medicine’s Next Phase of Growth
WALTHAM, Mass., May 9, 2024 Scipher Medicine, an AI-enabled precision immunology company, today announced the appointment of Reginald Seeto, MBBS*, as Chief Executive Officer and President. Scipher developed SpectraTM, a proprietary AI platform that has been...
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
Relationship leverages Quest’s sequencing and specimen collection expertise with Scipher’s precision medicine technology SECAUCUS, NJ and WALTHAM, MA – November 28, 2023 – Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services,...
Scipher Medicine Receives Medicare Coverage for PrismRA® Test in Rheumatoid Arthritis Patients
WALTHAM, Mass., September 7, 2023 – Scipher Medicine Corporation, a precision immunology company matching each patient with their most effective therapy, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), and Centers for Medicare and...
Scipher Medicine Signs Multi-Target Partnership with Ionis
Focus on development of precision therapeutics could lead to new and more effective treatments in disease areas including cardiovascular and CNS WALTHAM, Mass.--(July 17, 2023, BUSINESS WIRE)--Scipher Medicine today announced that it has entered into a multi-disease...
Scipher Medicine Acquires CrossBridge and its SaaS Platform to Collect and Map Patient Molecular, Outcomes and Claims Data in Real Time
First-of-its-kind technology stack in autoimmune diseases. Provides unprecedented insights into optimal patient treatment pathway. WALTHAM, Mass. (January 10, 2023) – ScipherMedicine, a precision immunology company matching each patient with their most effective...
Scipher Medicine Announces Publication of Positive Results From AIMS Clinical Study
Patients Were 3.1x More Likely to Reach Treatment Goals When Tested with PrismRA® Demonstrates Significantly Superior Outcomes Compared to Standard of Care in 3,348 Patient Analysis WALTHAM, Mass. (November 10, 2022) – Scipher Medicine announced data validating...
Galapagos In-licenses Novel Drug Targets for Inflammatory Bowel Disease Discovered by Scipher Medicine’s Spectra™ Platform
Collaboration Achieves Key Milestones After Preclinical Validation Work, Triggers Milestone Payment to Scipher WALTHAM, Mass. (May 24, 2022) – Scipher Medicine today announced that Galapagos (Euronext & NASDAQ: GLPG) has exercised its option to in-license...
Identifying TNFI Therapy Response in UC Patients Using Baseline Whole Blood Gene Expression Data
Shanthamallu, Uday Shankar ; Jones, Alexander ; Panés, Julián ; Corraliza Márquez, Ana Maria ; Salas, Azucena ; Akmaev, Slava ; Ghiassian, Susan Dina Background Non-response to TNF inhibitor (TNFi) therapies remains a challenge in UC/IBD management. Identification of...
Decision Impact Analysis to Measure the Influence of Molecular Signature Response Classifier Testing on Treatment Selection in Rheumatoid Arthritis
Jeffrey R Curtis 1, Vibeke Strand 2, Steven J Golombek 3, George A Karpouzas 4 5, Lixia Zhang 6, Angus Wong 6, Krishna Patel 6, Jennifer Dines 6, Viatcheslav R Akmaev 7 Introduction: Clinical guidelines offer little guidance for treatment selection following...
Confronting Step Therapy in Rheumatoid Arthritis: A Rheumatology Practice’s Experience Using PrismRA to Bypass Ineffective TNF Inhibitor Therapies
John Boone, Gary Crump and Rosie Walters Introduction Step Therapy (ST), also known as “Step Edit” or “Fail First”, is a policy adopted by third-party payers to minimize costs of prescription drug use by requiring patients to trial a less expensive, first-line...
Patient Perceptions of Rheumatoid Arthritis Blood Work: A Cross-sectional Survey in the ArthritisPower Registry
William Nowell1, Shilpa Venkatachalam2, Kelly Gavigan1, Michael George3, Johanna Withers4, Laura Stradford5, Esteban Rivera1 and Jeffrey Curtis6, 1Global Healthy Living Foundation, Upper Nyack, NY, 2Global Healthy Living Foundation, New York, NY, 3University of...
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
Vibeke Strand1, Emelly Rusli2, Lixia Zhang2, Christina Le-Short2, Alix Arnaud2, Johanna Withers3 and Sam Asgarian2, 1Stanford University School of Medicine, Stanford, CA, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corportaion, Waltham, MA...
Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)
Jeffrey Curtis1, Emelly Rusli2, Lixia Zhang2, Christina Le-Short2, Alix Arnaud2, Johanna Withers3 and Sam Asgarian2, 1University of Alabama at Birmingham, Hoover, AL, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corportaion, Waltham, MA...
Patient outcomes improve when a molecular signature test guides treatment decision-making in rheumatoid arthritis
Jeffrey R. Curtis; Vibeke Strand; Steven Golombek; Lixia Zhang; Angus Wong; Mark C. Zielinski; Viatcheslav R. Akmaev; Alif Saleh; Sam Asgarian; and Johanna B. Withers Background The molecular signature response classifier (MSRC) predicts tumor necrosis factor-ɑ...
Evaluation of physician global assessment in patients with b/tsDMARD therapy selection aligned with a molecular signature response classifier: an analysis from The Study to Accelerate Information of Molecular Signatures (AIMS) in Rheumatoid Arthritis
Johanna Withers, PhD; Lixia Zhang, PhD; Sam Asgarian, MD Presented at EULAR 2022 Copenhagen, Denmark - June 1-4, 2022 Background: Despite drug therapies that improve lives, tens of millions of patients annually are subjected to therapy using a “trial-and-error”...
A new test could save arthritis patients time, money and pain. But will it be used?
NPR SAN DIEGO — Dr. Erinn Maury knew Remicade wasn't the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte's swollen, painful joints hadn't responded to Enbrel or Humira, two drugs in the...
‘A ton of hurdles’ stand in the way of precision medicine for rheumatoid arthritis
Healio The slow march toward precision medicine in rheumatoid arthritis features increased use of serum biomarkers and novel approaches to biopsy, but “a ton of hurdles” remain, according to a presenter at the Biologic Therapies Summit. “We have been struggling for...
Can a Blood-Based Test Predict TNFi Nonresponse in RA?
Richard Mark Kirkner via Medscape A blood test that uses a patient’s unique genetic signature has shown some ability to predict nonresponse to tumor necrosis factor inhibitors as treatment for rheumatoid arthritis, an observational clinical study has found, but...
New Strategy for Avoiding Waste and Improving Response for Highest Cost Therapies in Rheumatoid Arthritis
AMCP Science & Innovation Theater Webinar Speakers: James T. Kenney, MBA, RPh, President, JTKENNEY, LLCAlif Saleh, CEO, Scipher Medicine Drug costs for targeted autoimmune diseases account for a large and growing proportion of pharmacy spend per patient. Despite...
Pandemic versus pandemonium: fighting on two fronts
The Lancet The ongoing COVID-19 pandemic has motivated many across the globe to adopt different approaches to understand the virus, surveil how the virus spreads, and search for effective treatments. This health crisis has focused global efforts on leveraging...
COVID-19 might be bitter medicine for what ails AI investing
Silicon AngleR. Danes Is investor belt-tightening brought on by COVID-19 the bitter medicine needed to bring sanity to the artificial intelligence funding bubble, flush out fakes, and shift venture capitalists’ attention to the most deserving companies? In...
Coronavirus: AI steps up in battle against Covid-19
BBCJane Wakefield, Technology Reporter Normally, just getting them all to work together would take "a year of paperwork", said Scipher's chief executive Alif Saleh. But a series of Zoom calls with a "group of people with a unprecedented determination to get things...
Scipher Medicine has developed a blood test expected to save payers billions each year
Optum Ventures is among companies investing $25 million, betting on the company's ability to show for which patients Humira doesn't work. Healthcare Finance NewsSusan Morse, Managing Editor Humira is the top-selling prescription drug by revenue. The biologic...
Spectra Logo
Download
PrismRA Logo – White
Download
PrismRA Logo – Black
Download
Scipher Medicine Logo – White
Scipher-Logo-White-1Download
Scipher Medicine Lab Image
Scipher_Medicine_STAT_ImageDownload
Scipher Medicine – Corporate Logo
Download